INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) investors concerning the Company’s possible violations of federal securities laws.

On July 22, 2024, Allarity disclosed that it had received a Wells Notice from the U.S. Securities and Exchange Commission relating to the Company’s statements regarding meetings with the U.S. Food and Drug Administration about the Company’s NDA for its drug, Dovitnib, which was submitted in 2021. Three of Allarity’s former officers also received Wells Notices, wherein the SEC Staff stated it “has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws.”

If you purchased Allarity securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone] or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.